Focuses on developing antibiotics to treat infections caused by multi-drug resistant pathogens, aiming to address unmet medical needs in infectious diseases.
Iterum Therapeutics plc is a clinical-stage pharmaceutical company dedicated to advancing anti-infective therapies across Ireland, Bermuda, and the United States. At the forefront of its pipeline is sulopenem, a groundbreaking anti-infective compound available in both oral and intravenous formulations. Currently in Phase III clinical trials, sulopenem aims to address critical medical needs by targeting uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.
Founded in 2015 and headquartered in Dublin, Ireland, Iterum Therapeutics plc has positioned itself as a leader in the development and potential commercialization of innovative treatments for infectious diseases. The company's mission underscores its commitment to delivering effective solutions that meet the evolving challenges posed by bacterial infections, thereby enhancing patient outcomes and healthcare efficacy.
Iterum Therapeutics plc continues to leverage its scientific expertise and strategic partnerships to advance sulopenem through rigorous clinical evaluation. With a robust pipeline and a strong emphasis on research and development, the company aims to make significant contributions to the global fight against infectious diseases.